Patients with IBD are randomized to oral administration of vitamin B5 and placebo based on the standard treatment, exploring whether Vitamin B5 can increase the clinical remission rate of IBD patients and improve the treatment effect.

Inclusion Criteria:

• Patients diagnosed with IBD according to the consensus on the diagnosis and treatment of inflammatory bowel disease (Beijing, 2018, DOI:10.19538/j.nk2018090106);
• Have complete medical history data;
• Volunteer to participate in this clinical trial and sign the informed consent form.

Exclusion Criteria:

• Hemophilic patients;
• There are abdominal abscesses, toxic megacolon, fulminant colitis, partial colectomy, or total colectomy;
• Other autoimmune diseases, hematological diseases, tumors, acute infection, severe liver and kidney insufficiency, serious diseases such as severe anemia, neutropenia, heart failure, organic heart disease, hepatitis B, liver cirrhosis, kidney disease and mental diseases;
• Take calcium pantothenate preparation in recent 3 months;
• Have a history of abuse of psychoactive substances;
• Pregnant or lactating women, or plan to be pregnant in the next 6 months;
• Nervous system diseases: such as Alzheimer's disease, stroke, Parkinson's disease;
• Participate in other clinical trials in the past 6 months;
• Incomplete medical record information (including gender, age, diagnosis information, colonoscopy results, pathological diagnosis results and other demographic data)